[Trends in urology].
The systemic treatment of kidney cancers is promising regarding the first results of the inhibiting molecules of the angiogenesis. Projections in research are encouraging for more specific and sensitive markers of the prostate cancer. For this last the intermittent hormonotherapy improves the quality of life of the patients. The overweight control in infertility allows greater chances of giving birth. The morbidity of the kidney percutaneous surgery is decreased by the use of smaller tools. Reduction rate of reobstruction thanks to new manufactoring stents. The botulinic toxin for the hyperactive bladder refunded by the health insurances.
Uffer
Matieu
M
Service d'urologie, CHUV, Lausanne. Matieu.Uffer@chuv.ch
Chollet
Yves
Y
Cardinaux
Céclie
C
Erling
Christoph
C
Praz
Valentin
V
Ramadani
Dursim
D
Tawadros
Thomas
T
Treutherdt
Cédric
C
Wisard
Marc
M
Zarkik
Yassin
Y
Jichlinski
Patrice
P
D000951:Antigens, Neoplasm / Q000032:analysis; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009465:Neuromuscular Agents / Q000627:therapeutic use; D015607:Stents; D014570:Urologic Diseases / Q000175:diagnosis* / Q000628:therapy*
D000951:Antigens, Neoplasm; D009465:Neuromuscular Agents; C479341:prostate cancer antigen 3, human; D019274:Botulinum Toxins, Type A